



cancers



an Open Access Journal by MDPI

Innovative Immunotherapies: CAR-T Cell Therapy for Cancers

Guest Editor:

Dr. Shebli Atrash

Levine Cancer Institute,
Charlotte, NC 28204, USA

Deadline for manuscript
submissions:

13 December 2024

Message from the Guest Editor

Dear colleagues,

Immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Innovative immunotherapies, such as CAR-T, have shown advantageous outcomes in various cancer types. By modifying a patient's T cells, CAR-T targets specific antigens in the cancer cells. This precision targeting allows for a particular attack on cancer cells while minimizing damage to healthy cells. However, it is important to note that CAR-T therapy has some encumbrances and challenges. For example, it can be associated with significant side effects, including cytokine release syndrome and neurotoxicity. Improving CAR-T involves better target selection, higher potency, longer persistency, and overcoming resistance mechanisms that are employed by the cancer cells to evade/escape the immune system. In this Special Issue, we will encourage novel approaches and perspectives of CAR-T cell therapy for cancers.

Dr. Shebli Atrash

Guest Editor



mdpi.com/si/173596

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI